Company AnnouncementNet sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & ...

The CEPHEUS trial is a trial for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplantation, or in whom a transplant was deferred. And 395 patients were randomized ...

Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...

Please provide your email address to receive an email when new articles are posted on . The daratumumab-based regimen conferred significantly longer PFS than standard of care. Three-quarters of ...

Daratumumab (anti-CD38) and elotuzumab (anti-SLAMF7) have ushered in a new era in the treatment of multiple myeloma. Like the treatments for lymphomas and breast cancer, these monoclonal antibodies ...

Sagar Lonial, MD, FACP: We very recently saw data presented by Dr. Mateos on behalf of her investigators in a randomized phase III trial of MPV—melphalan, prednisone, and bortezomib—versus MPV ...

Please provide your email address to receive an email when new articles are posted on . Adding daratumumab to backbone regimens improved PFS for patients with multiple myeloma and high-risk ...

SAN DIEGO, April 9, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European ...

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of indication for teclistamab in combination with subcutaneous daratumumab for adults ...

Data from the Apollo study provide proof for the subcutaneous administration (sc) of daratumumab (Darzalex Faspro) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for patients with ...